Vertex Pharma (VRTX) Tops Q1 EPS by 2c; Reaffirms
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $505.75 -2.07%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $3.05, $0.02 better than the analyst estimate of $3.03. Revenue for the quarter came in at $2.37 billion versus the consensus estimate of $2.34 billion.
GUIDANCE:
Vertex Pharma reaffirms FY2023 revenue of $9.55-9.7 billion, versus the consensus of $9.7 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Reading (RDI) Tops Q2 EPS by 4c
- Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
